27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The upcoming week could see some action due to the presence of a host of catalytic events that include PDUFA dates and earnings releases. Here are are the ones a biotech investor should keep a tab on.
Conferences
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- Alzheimer's Association International Conference, or AAIC – July 22-26, in Chicago
- 20th World Dermatology and Aesthetic Congress - July 23-24 in Kuala Lumpur , Malaysia
- 13th Global Dermatologists Congress - July 23-24 in Moscow, Russia
- Global Meeting on Diabetes and Endocrinology - July 23-24 in Kuala Lumpur, Malaysia
- Annual Biotechnology Congress - July 23-24 in Vancouver, Canada
- 24th International Conference on Neuroscience and Neurochemistry - July 23-24, in Birmingham, UK
- 6th International Congress on Gynecology & Gynecologic Oncology - July 23-24 in Rome, Italy
- 11th International Conference on Vascular Dementia - July 23-25 in Moscow, Russia
- 29th Euro-Global Summit on Cancer Therapy & Radiation Oncology - July 23-25 in Rome, Italy
- 27th Euro-Global Neurologists Meeting - July 23 – 25 in Moscow, Russia
- 5th World Congress on Mental Health and Well-being - July 25-26 in Pacific Gateway Hotel at Vancouver Airport, British Columbia, Vancouver, Canada
- 20th Annual congress on Eating Disorders, Obesity and Nutrition - July 26-27 in Amsterdam, Netherlands
- 11th International Virology and Microbiology - July 27-28 in Vancouver, Canada
- 2nd International Conference on Women`s Health, Obstetrics and Female Reproductive System - July 27-28 in Vancouver, Canada
PDUFA Dates
The FDA is set to rule on Insys Therapeutics Inc (NASDAQ:INSY)'s NDA for its Buprenorphine sublingual spray on July 28. The candidate is being evaluated for moderate-to-severe postoperative pain after bunionectomy.
DURECT Corporation (NASDAQ:DRRX)'s schizophrenia treatment candidate RBP-7000, which has been licensed to U.K.-based biotech INDIVIOR PLC/S ADR (OTC:INVVY) has a PDUFA action date of July 28.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and AbbVie Inc (NYSE:ABBV) await FDA verdict on their Elagolix for acute endometriosis-associated pain. Although the exact PDUFA date wasn't announced, based on the three-month extension in the review period announced by the FDA on April 10, the decision could come through in July or early August.
Adcom Meeting
FDA's Pulmonary-Allergy Drugs Advisory Committee is set to discuss GlaxoSmithKline plc (ADR) (NYSE:GSK)'s sBLA for mepolizumab injection, which is evaluated as an add-on treatment to inhaled corticosteroid-based maintenance treatment for the reduction of exacerbations in patients with chronic obstructive pulmonary disease. The Adcom meeting is scheduled for July 25.
Clinical Trial Results
Biogen Inc (NASDAQ:BIIB) is scheduled to present Phase 2 data for its BAN2401 to treat Alzheimer's disease at the AAIC on July 25. The data released July 5 showed the treatment candidate slowed disease progression.
Probable Releases (Mid-2018/Early Q3 Schedule)
BIOLINERX Ltd/S ADR (NASDAQ:BLRX) is due to release Phase 3 data for its BL-8040, evaluated in a study called GENESIS to treat stem-cell mobilization for autologous transplantation.
GlaxoSmithKline plc (ADR) (NYSE:GSK) could release Phase 2b data for its amyloidosis treatment anti-SAP mAb.
Altimmune Inc (NASDAQ:ALT) is scheduled to release Phase 1data for its anthrax vaccine candidate Nasoshield.
Galectin Therapeutics Inc. (NASDAQ:GALT) is set to release Phase 1 data for its melanoma treatment combo GR-MD-02 and Keytruda. The data is key as it will determine whether the company will proceed with Phase 2 trials.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
See Also: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year
Earnings
Monday
Veracyte Inc (NASDAQ:VCYT)
Tuesday
Eli Lilly And Co (NYSE:LLY)
Biogen Inc (NASDAQ:BIIB)
Wednesday
Laboratory Corp. of America (NYSE:LH)
Anika Therapeutics Inc (NASDAQ:ANIK)
Gilead Sciences, Inc. (NASDAQ:GILD)
Varian Medical Systems, Inc. (NYSE:VAR)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Thursday
Allergan plc (NYSE:AGN)
ABIOMED, Inc. (NASDAQ:ABMD)
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Amgen, Inc. (NASDAQ:AMGN)
Baxter International Inc (NYSE:BAX)
Cytokinetics, Inc. (NASDAQ:CYTK)
Edwards Lifesciences Corp (NYSE:EW)
Celgene Corporation (NASDAQ:CELG)
Seattle Genetics, Inc. (NASDAQ:SGEN)
Retrophin Inc (NASDAQ:RTRX)
Friday
AbbVie Inc (NYSE:ABBV)
Zimmer Biomet Holdings Inc (NYSE:ZBH)
IPO
Aquestive Therapeutics, a company focused on differentiated therapy products to address unmet medical needs, is set to offer 4 million shares in an IPO, with an estimated price range of $14-$16. The company seeks to list its shares on the Nasdaq under the ticker symbol AQST.
Liquidia Technologies will offer 4.55 million shares in an IPO, priced between $10 and $12. The shares are to be listed on the Nasdaq under the ticker symbol LQDA.
IPO Quiet Period Expiry
Neon Therapeutics Inc (NASDAQ:NTGN)
Forty Seven Inc (NASDAQ:FTSV)
Entera Bio Ltd (NASDAQ:ENTX)
Tricida Inc (NASDAQ:TCDA)
Neuronetics Inc (NASDAQ:STIM)
Translate Bio Inc (NASDAQ:TBIO)
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.